NELFCD and non-small cell lung carcinoma: Despite these limitations, to the best of our knowledge, our study is the first to identify pretreatment Th1/Th2 cytokine levels in the peripheral blood of patients with NSCLC as potential indicators of response efficacy of and survival benefits from anti-PD-1/PD-L1 immunotherapy.